FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763080742> ?p ?o ?g. }

• W2763080742 endingPage "94316" @default.
• W2763080742 startingPage "94297" @default.
• W2763080742 abstract "// Dong Woo Yeom 1, * , Bo Ram Chae 1, 2, * , Jin Han Kim 1 , Jun Soo Chae 1 , Dong Jun Shin 1 , Chang Hyun Kim 1 , Sung Rae Kim 1 , Ji Ho Choi 1 , Seh Hyon Song 2 , Dongho Oh 2 , Se Il Sohn 2 and Young Wook Choi 1 1 College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea 2 Daewon Pharm. Co., Ltd, Seoul 04994, Republic of Korea * These authors have contributed equally to this work Correspondence to: Young Wook Choi, email: ywchoi@cau.ac.kr Keywords: valsartan; SMEDDS; solid carrier; tablet; optimization Received: June 27, 2017     Accepted: September 20, 2017     Published: October 09, 2017 ABSTRACT In order to improve the dissolution and oral bioavailability of valsartan (VST), and reduce the required volume for treatment, we previously formulated a supersaturable self-microemulsifying drug delivery system (SuSMEDDS) composed of VST (80 mg), Capmul ® MCM (13.2 mg), Tween ® 80 (59.2 mg), Transcutol ® P (59.2 mg), and Poloxamer 407 (13.2 mg). In the present study, by using Florite ® PS-10 (119.1 mg) and Vivapur ® 105 (105.6 mg) as solid carriers, VST-loaded solidified SuSMEDDS (S-SuSMEDDS) granules were successfully developed, which possessed good flow properties and rapid drug dissolution. By introducing croscarmellose sodium (31 mg) as a superdisintegrant, S-SuSMEDDS tablets were also successfully formulated, which showed fast disintegration and high dissolution efficiency. Preparation of granules and tablets was successfully optimized using D-optimal mixture design and 3-level factorial design, respectively, resulting in percentage prediction errors of <10%. In pharmacokinetic studies in rats, the relative bioavailability of the optimized granules was 107% and 222% of values obtained for SuSMEDDS and Diovan ® powder, respectively. Therefore, we conclude that novel S-SuSMEDDS formulations offer great potential for developing solid dosage forms of a liquefied formulation such as SuSMEDDS, while improving oral absorption of drugs with poor water solubility." @default.
• W2763080742 created "2017-10-20" @default.
• W2763080742 creator A5003485608 @default.
• W2763080742 creator A5020669081 @default.
• W2763080742 creator A5028123335 @default.
• W2763080742 creator A5030455706 @default.
• W2763080742 creator A5042971121 @default.
• W2763080742 creator A5043332842 @default.
• W2763080742 creator A5066246875 @default.
• W2763080742 creator A5068890547 @default.
• W2763080742 creator A5068911195 @default.
• W2763080742 creator A5073469832 @default.
• W2763080742 creator A5081334160 @default.
• W2763080742 creator A5084900880 @default.
• W2763080742 date "2017-10-09" @default.
• W2763080742 modified "2023-09-27" @default.
• W2763080742 title "Solid formulation of a supersaturable self-microemulsifying drug delivery system for valsartan with improved dissolution and bioavailability" @default.
• W2763080742 cites W1438918166 @default.
• W2763080742 cites W1971913759 @default.
• W2763080742 cites W1973073798 @default.
• W2763080742 cites W1979289583 @default.
• W2763080742 cites W1979756386 @default.
• W2763080742 cites W1980249850 @default.
• W2763080742 cites W1996507918 @default.
• W2763080742 cites W1999026740 @default.
• W2763080742 cites W2001196260 @default.
• W2763080742 cites W2014297898 @default.
• W2763080742 cites W2024345680 @default.
• W2763080742 cites W2033158497 @default.
• W2763080742 cites W2050835700 @default.
• W2763080742 cites W2052265032 @default.
• W2763080742 cites W2055663558 @default.
• W2763080742 cites W2062441183 @default.
• W2763080742 cites W2064845818 @default.
• W2763080742 cites W2069217160 @default.
• W2763080742 cites W2071835288 @default.
• W2763080742 cites W2071917103 @default.
• W2763080742 cites W2077812525 @default.
• W2763080742 cites W2079954610 @default.
• W2763080742 cites W2081026009 @default.
• W2763080742 cites W2086599022 @default.
• W2763080742 cites W2087908293 @default.
• W2763080742 cites W2088142318 @default.
• W2763080742 cites W2090676307 @default.
• W2763080742 cites W2096080637 @default.
• W2763080742 cites W2102301444 @default.
• W2763080742 cites W2109579771 @default.
• W2763080742 cites W2151114776 @default.
• W2763080742 cites W2159269801 @default.
• W2763080742 cites W2269860517 @default.
• W2763080742 cites W2330083040 @default.
• W2763080742 cites W2336436849 @default.
• W2763080742 cites W2397302576 @default.
• W2763080742 cites W2513088687 @default.
• W2763080742 cites W2612534502 @default.
• W2763080742 cites W886433868 @default.
• W2763080742 doi "https://doi.org/10.18632/oncotarget.21691" @default.
• W2763080742 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5706875" @default.
• W2763080742 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29212229" @default.
• W2763080742 hasPublicationYear "2017" @default.
• W2763080742 type Work @default.
• W2763080742 sameAs 2763080742 @default.
• W2763080742 citedByCount "19" @default.
• W2763080742 countsByYear W27630807422018 @default.
• W2763080742 countsByYear W27630807422019 @default.
• W2763080742 countsByYear W27630807422020 @default.
• W2763080742 countsByYear W27630807422021 @default.
• W2763080742 countsByYear W27630807422022 @default.
• W2763080742 countsByYear W27630807422023 @default.
• W2763080742 crossrefType "journal-article" @default.
• W2763080742 hasAuthorship W2763080742A5003485608 @default.
• W2763080742 hasAuthorship W2763080742A5020669081 @default.
• W2763080742 hasAuthorship W2763080742A5028123335 @default.
• W2763080742 hasAuthorship W2763080742A5030455706 @default.
• W2763080742 hasAuthorship W2763080742A5042971121 @default.
• W2763080742 hasAuthorship W2763080742A5043332842 @default.
• W2763080742 hasAuthorship W2763080742A5066246875 @default.
• W2763080742 hasAuthorship W2763080742A5068890547 @default.
• W2763080742 hasAuthorship W2763080742A5068911195 @default.
• W2763080742 hasAuthorship W2763080742A5073469832 @default.
• W2763080742 hasAuthorship W2763080742A5081334160 @default.
• W2763080742 hasAuthorship W2763080742A5084900880 @default.
• W2763080742 hasBestOaLocation W27630807421 @default.
• W2763080742 hasConcept C101335993 @default.
• W2763080742 hasConcept C126322002 @default.
• W2763080742 hasConcept C15920480 @default.
• W2763080742 hasConcept C171250308 @default.
• W2763080742 hasConcept C178790620 @default.
• W2763080742 hasConcept C181389837 @default.
• W2763080742 hasConcept C185592680 @default.
• W2763080742 hasConcept C192562407 @default.
• W2763080742 hasConcept C2777091354 @default.
• W2763080742 hasConcept C2777387769 @default.
• W2763080742 hasConcept C2778572730 @default.
• W2763080742 hasConcept C2779820397 @default.
• W2763080742 hasConcept C2780306666 @default.
• W2763080742 hasConcept C43617362 @default.
• W2763080742 hasConcept C521977710 @default.

• next